المؤلفون: Xu M; The Second Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou, 310000, China.; Department of Clinical Trial, Zhejiang Cancer Hospital, Hangzhou, 310022, Zhejiang, China., Shao K; Department of Clinical Trial, Zhejiang Cancer Hospital, Hangzhou, 310022, Zhejiang, China.; Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, 310018, Zhejiang, China., Wang Y; The Second Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou, 310000, China.; Department of Clinical Trial, Zhejiang Cancer Hospital, Hangzhou, 310022, Zhejiang, China., Hao Y; The Second Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou, 310000, China. deartreasurealicia@163.com.; Department of Clinical Trial, Zhejiang Cancer Hospital, Hangzhou, 310022, Zhejiang, China. deartreasurealicia@163.com., Song Z; Department of Clinical Trial, Zhejiang Cancer Hospital, Hangzhou, 310022, Zhejiang, China. songzb@zjcc.org.cn.; Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, 310018, Zhejiang, China. songzb@zjcc.org.cn.

المصدر: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico [Clin Transl Oncol] 2024 Jul; Vol. 26 (7), pp. 1687-1695. Date of Electronic Publication: 2024 Feb 16.

نوع المنشور: Journal Article; Comparative Study

بيانات الدورية: Publisher: Country of Publication: Italy NLM ID: 101247119 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1699-3055 (Electronic) Linking ISSN: 1699048X NLM ISO Abbreviation: Clin Transl Oncol Subsets: MEDLINE

مواضيع طبية MeSH: Indoles*/therapeutic use , Indoles*/administration & dosage , Indoles*/adverse effects , Quinolines*/therapeutic use , Quinolines*/adverse effects , Quinolines*/administration & dosage , Small Cell Lung Carcinoma*/drug therapy , Small Cell Lung Carcinoma*/pathology , Immune Checkpoint Inhibitors*/therapeutic use , Immune Checkpoint Inhibitors*/adverse effects , Immune Checkpoint Inhibitors*/administration & dosage , Brain Neoplasms*/secondary , Brain Neoplasms*/drug therapy , Lung Neoplasms*/drug therapy , Lung Neoplasms*/pathology , Antineoplastic Combined Chemotherapy Protocols*/therapeutic use , Antineoplastic Combined Chemotherapy Protocols*/adverse effects, Humans ; Male ; Female ; Middle Aged ; Aged ; Progression-Free Survival ; Retrospective Studies ; Adult ; Aged, 80 and over ; Kaplan-Meier Estimate

المؤلفون: Zhang X; Precision Medicine Center of Oncology, The Affiliated Hospital of Qingdao University, No. 59 Haier Road, Qingdao, Shandong, 266035, China., Zhang H; Department of Thoracic Surgery, The Affiliated Hospital of Qingdao University, No. 59 Haier Road, Qingdao, Shandong, 266035, China., Hou F; Department of Pathology, The Affiliated Hospital of Qingdao University, Qingdao University, No.59 Haier Road, Qingdao, 266035, China., Fang T; Department of Oncology, Shengli Oilfield Central Hospital, No.31 Jinan Road, Dongying, Shandong, 257099, China., Zhang C; Department of Oncology, The Affiliated Hospital of Qingdao University, No. 7 Jiaxing Road, Qingdao, Shandong, 266031, China., Wang H; Department of Oncology, The Affiliated Hospital of Qingdao University, No. 7 Jiaxing Road, Qingdao, Shandong, 266031, China., Song S; Department of Oncology, The Affiliated Hospital of Qingdao University, No. 7 Jiaxing Road, Qingdao, Shandong, 266031, China., Lan H; Precision Medicine Center of Oncology, The Affiliated Hospital of Qingdao University, No. 59 Haier Road, Qingdao, Shandong, 266035, China., Wang Y; Department of Thoracic Surgery, The Affiliated Hospital of Qingdao University, No. 59 Haier Road, Qingdao, Shandong, 266035, China. wyjtgzy@163.com., Hou H; Department of Oncology, The Affiliated Hospital of Qingdao University, No. 7 Jiaxing Road, Qingdao, Shandong, 266031, China. houheleihhl@163.com.

المصدر: World journal of surgical oncology [World J Surg Oncol] 2024 Jun 18; Vol. 22 (1), pp. 159. Date of Electronic Publication: 2024 Jun 18.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: BioMed Central Country of Publication: England NLM ID: 101170544 Publication Model: Electronic Cited Medium: Internet ISSN: 1477-7819 (Electronic) Linking ISSN: 14777819 NLM ISO Abbreviation: World J Surg Oncol Subsets: MEDLINE

مواضيع طبية MeSH: Carcinoma, Non-Small-Cell Lung*/drug therapy , Carcinoma, Non-Small-Cell Lung*/pathology , Carcinoma, Non-Small-Cell Lung*/genetics , Lung Neoplasms*/drug therapy , Lung Neoplasms*/pathology , Lung Neoplasms*/genetics , Neoadjuvant Therapy*/methods , Antineoplastic Combined Chemotherapy Protocols*/therapeutic use , B7-H1 Antigen*/antagonists & inhibitors , B7-H1 Antigen*/metabolism , Immune Checkpoint Inhibitors*/therapeutic use, Humans ; Female ; Male ; Middle Aged ; Retrospective Studies ; Aged ; Follow-Up Studies ; Survival Rate ; Adult ; Prognosis ; Oncogenes/genetics ; Protein Kinase Inhibitors/therapeutic use ; Mutation ; Programmed Cell Death 1 Receptor/antagonists & inhibitors ; Programmed Cell Death 1 Receptor/metabolism

المؤلفون: Li S; Department of Oncology, Binzhou Medical University Hospital, Binzhou, Shandong, People's Republic of China., Yu ZS; Department of Oncology, Binzhou Medical University Hospital, Binzhou, Shandong, People's Republic of China., Liu HZ; Department of Orthopedics, Binzhou Medical University Hospital, Binzhou, Shandong, People's Republic of China., Li SJ; Department of Oncology, Binzhou Medical University Hospital, Binzhou, Shandong, People's Republic of China., Wang MY; Department of Oncology, Binzhou Medical University Hospital, Binzhou, Shandong, People's Republic of China., Ning FL; Department of Oncology, Binzhou Medical University Hospital, Binzhou, Shandong, People's Republic of China., Tian LJ; Department of Oncology, Binzhou Medical University Hospital, Binzhou, Shandong, People's Republic of China.

المصدر: Cancer medicine [Cancer Med] 2024 Jun; Vol. 13 (11), pp. e7349.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: John Wiley & Sons Ltd Country of Publication: United States NLM ID: 101595310 Publication Model: Print Cited Medium: Internet ISSN: 2045-7634 (Electronic) Linking ISSN: 20457634 NLM ISO Abbreviation: Cancer Med Subsets: MEDLINE

مواضيع طبية MeSH: Angiogenesis Inhibitors*/therapeutic use , Angiogenesis Inhibitors*/adverse effects , Antineoplastic Combined Chemotherapy Protocols*/therapeutic use , Antineoplastic Combined Chemotherapy Protocols*/adverse effects , Carcinoma, Non-Small-Cell Lung*/drug therapy , Carcinoma, Non-Small-Cell Lung*/pathology , Carcinoma, Non-Small-Cell Lung*/mortality , Carcinoma, Non-Small-Cell Lung*/therapy , Endostatins*/therapeutic use , Endostatins*/administration & dosage , Immunotherapy*/methods , Lung Neoplasms*/drug therapy , Lung Neoplasms*/pathology , Lung Neoplasms*/mortality , Lung Neoplasms*/therapy , Neoplasm Staging*, Adult ; Aged ; Aged, 80 and over ; Female ; Humans ; Male ; Middle Aged ; Antibodies, Monoclonal, Humanized/therapeutic use ; Antibodies, Monoclonal, Humanized/administration & dosage ; Bevacizumab/therapeutic use ; Bevacizumab/administration & dosage ; Indoles/therapeutic use ; Quality of Life ; Quinolines/therapeutic use ; Retrospective Studies

المؤلفون: Yang JC; Department of Oncology, National Taiwan University Hospital and National Taiwan University Cancer Center, Taipei, Taiwan, Republic of China. Electronic address: chihyang@ntu.edu.tw., Han B; Department of Pulmonary, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, People's Republic of China., De La Mora Jiménez E; Instituto Jalisciense de Cancerologia, Guadalajara, Mexico., Lee JS; Internal Medicine, Seoul National University College of Medicine, Seoul, South Korea., Koralewski P; Ludwik Rydygier Memorial Specialist Hospital, Krakow, Poland., Karadurmus N; Gulhane Training and Research Hospital, Ankara, Turkey., Sugawara S; Department of Pulmonary Medicine, Sendai Kousei Hospital, Sendai, Miyagi, Japan., Livi L; Department of Experimental and Biomedical Sciences Mario Serio, University of Florence and Radiation Oncology Unit, Oncology Department, Azienda Ospedaliero Universitaria Careggi, Florence, Italy., Basappa NS; Cross Cancer Institute, University of Alberta, Edmonton, AB, Canada., Quantin X; IRCM, INSERM, University of Montpellier, ICM, Montpellier, France., Dudnik J; Soroka Medical Center, Beer-Sheva, Israel., Ortiz DM; Fundacion Centro de Investigacion Clinica CIC, Medellin, Colombia., Mekhail T; Advent Health Cancer Institute, Orlando, Florida., Okpara CE; Eisai Ltd., Hatfield, United Kingdom., Dutcus C; Eisai Inc., Nutley, New Jersey., Zimmer Z; Merck & Co., Inc., Rahway, New Jersey., Samkari A; Merck & Co., Inc., Rahway, New Jersey., Bhagwati N; Merck & Co., Inc., Rahway, New Jersey., Csőszi T; Hetenyi Geza Korhaz, Szolnok, Hungary.

المصدر: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer [J Thorac Oncol] 2024 Jun; Vol. 19 (6), pp. 941-953. Date of Electronic Publication: 2023 Dec 29.

نوع المنشور: Journal Article; Randomized Controlled Trial; Clinical Trial, Phase III; Multicenter Study

بيانات الدورية: Publisher: Elsevier Country of Publication: United States NLM ID: 101274235 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1556-1380 (Electronic) Linking ISSN: 15560864 NLM ISO Abbreviation: J Thorac Oncol Subsets: MEDLINE

مواضيع طبية MeSH: Quinolines*/therapeutic use , Carcinoma, Non-Small-Cell Lung*/drug therapy , Carcinoma, Non-Small-Cell Lung*/pathology , Antibodies, Monoclonal, Humanized*/therapeutic use , Lung Neoplasms*/drug therapy , Lung Neoplasms*/pathology , Phenylurea Compounds*/therapeutic use , Antineoplastic Combined Chemotherapy Protocols*/therapeutic use, Humans ; Male ; Female ; Double-Blind Method ; Middle Aged ; Aged ; Adult ; B7-H1 Antigen/metabolism ; B7-H1 Antigen/antagonists & inhibitors ; Aged, 80 and over

المؤلفون: Toubat O; Division of Thoracic Surgery, Department of Surgery, Keck School of Medicine of USC, Los Angeles, California., Ding L; Department of Population and Public Health Sciences, Keck School of Medicine of USC, Los Angeles, California., Ding K; Department of Public Health Sciences, Canadian Cancer Trials Group, Queen's University, Kingston, Ontario, Canada., Wightman SC; Division of Thoracic Surgery, Department of Surgery, Keck School of Medicine of USC, Los Angeles, California., Atay SM; Division of Thoracic Surgery, Department of Surgery, Keck School of Medicine of USC, Los Angeles, California., Harano T; Division of Thoracic Surgery, Department of Surgery, Keck School of Medicine of USC, Los Angeles, California., Kim AW; Division of Thoracic Surgery, Department of Surgery, Keck School of Medicine of USC, Los Angeles, California., David EA; Division of Cardiothoracic Surgery, Department of Surgery, University of Colorado School of Medicine, Aurora, Colorado. Electronic address: elizabeth.david@cuanschutz.edu.

المصدر: Seminars in thoracic and cardiovascular surgery [Semin Thorac Cardiovasc Surg] 2024 Summer; Vol. 36 (2), pp. 261-270. Date of Electronic Publication: 2022 Oct 20.

نوع المنشور: Journal Article; Randomized Controlled Trial; Clinical Trial, Phase III

بيانات الدورية: Publisher: W.B. Saunders Country of Publication: United States NLM ID: 8917640 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1532-9488 (Electronic) Linking ISSN: 10430679 NLM ISO Abbreviation: Semin Thorac Cardiovasc Surg Subsets: MEDLINE

مواضيع طبية MeSH: Carcinoma, Non-Small-Cell Lung*/mortality , Carcinoma, Non-Small-Cell Lung*/pathology , Carcinoma, Non-Small-Cell Lung*/surgery , Carcinoma, Non-Small-Cell Lung*/drug therapy , Lung Neoplasms*/mortality , Lung Neoplasms*/pathology , Lung Neoplasms*/drug therapy , Lung Neoplasms*/surgery , Pneumonectomy*/adverse effects , Pneumonectomy*/mortality , Cisplatin*/administration & dosage , Antineoplastic Combined Chemotherapy Protocols*/adverse effects , Antineoplastic Combined Chemotherapy Protocols*/therapeutic use , Neoplasm Staging* , Vinorelbine*/adverse effects , Vinorelbine*/administration & dosage, Humans ; Chemotherapy, Adjuvant ; Female ; Male ; Middle Aged ; Aged ; Time Factors ; Risk Factors ; Treatment Outcome ; Risk Assessment ; North America ; Progression-Free Survival

المؤلفون: Yamamoto N; Department of Experimental Therapeutics, National Cancer Center Hospital, 5 Chome-1-1 Tsukiji, Tokyo, Japan. nbryamam@ncc.go.jp., Satouchi M; Department of Thoracic Oncology, Hyogo Cancer Center, Akashi, Japan., Doi T; Department of Experimental Therapeutics, National Cancer Center Hospital East, Kashiwa, Japan., Fujiwara Y; Department of Experimental Therapeutics, National Cancer Center Hospital, 5 Chome-1-1 Tsukiji, Tokyo, Japan.; Department of Thoracic Oncology, Aichi Cancer Center, Aichi, Japan., Yanagitani N; Department of Thoracic Medical Oncology, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan., Kawa Y; Department of Thoracic Oncology, Hyogo Cancer Center, Akashi, Japan., Yoh K; Department of Experimental Therapeutics, National Cancer Center Hospital East, Kashiwa, Japan., Leopold L; Incyte Corporation, Clinical Development, Wilmington, DE, USA., Munteanu M; Incyte Corporation, Clinical Development, Wilmington, DE, USA., Sawada T; MSD K.K. Oncology Science Unit, Tokyo, Japan., Han S; MSD K.K. Oncology Science Unit, Tokyo, Japan., Noguchi K; MSD K.K. Oncology Science Unit, Tokyo, Japan., Nishio M; Department of Thoracic Medical Oncology, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan.

المصدر: Investigational new drugs [Invest New Drugs] 2024 Jun; Vol. 42 (3), pp. 261-271. Date of Electronic Publication: 2024 Mar 26.

نوع المنشور: Journal Article; Clinical Trial, Phase I; Multicenter Study

بيانات الدورية: Publisher: Springer Country of Publication: United States NLM ID: 8309330 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1573-0646 (Electronic) Linking ISSN: 01676997 NLM ISO Abbreviation: Invest New Drugs Subsets: MEDLINE

مواضيع طبية MeSH: Carcinoma, Non-Small-Cell Lung*/drug therapy , Carcinoma, Non-Small-Cell Lung*/pathology , Antineoplastic Combined Chemotherapy Protocols*/adverse effects , Antineoplastic Combined Chemotherapy Protocols*/therapeutic use , Antineoplastic Combined Chemotherapy Protocols*/administration & dosage , Lung Neoplasms*/drug therapy , Lung Neoplasms*/pathology , Antibodies, Monoclonal, Humanized*/adverse effects , Antibodies, Monoclonal, Humanized*/administration & dosage , Antibodies, Monoclonal, Humanized*/therapeutic use, Humans ; Male ; Female ; Middle Aged ; Aged ; Oximes/administration & dosage ; Oximes/adverse effects ; Oximes/therapeutic use ; Adult ; Sulfonamides/administration & dosage ; Sulfonamides/therapeutic use ; Sulfonamides/adverse effects ; Pemetrexed/administration & dosage ; Pemetrexed/therapeutic use ; Pemetrexed/adverse effects ; Carboplatin/administration & dosage ; Carboplatin/therapeutic use ; Carboplatin/adverse effects ; Japan ; Cisplatin/administration & dosage ; Cisplatin/adverse effects ; Cisplatin/therapeutic use ; East Asian People

المؤلفون: Katayama Y; Department of Pulmonary Medicine, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan., Yamada T; Department of Pulmonary Medicine, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan., Sawada R; Department of Pulmonary Medicine, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan., Kawachi H; Department of Pulmonary Medicine, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan., Morimoto K; Department of Pulmonary Medicine, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan., Watanabe S; Department of Respiratory Medicine and Infectious Diseases, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan., Watanabe K; Department of Thoracic Oncology and Respiratory Medicine, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo, Japan., Takeda T; Department of Respiratory Medicine, Japanese Red Cross Kyoto Daini Hospital, Kyoto, Japan., Chihara Y; Department of Respiratory Medicine, Uji-Tokushukai Medical Center, Kyoto, Japan., Shiotsu S; Department of Respiratory Medicine, Japanese Red Cross Kyoto Daiichi Hospital, Kyoto, Japan., Hibino M; Department of Respiratory Medicine, Shonan Fujisawa Tokushukai Hospital, Kanagawa, Japan., Harada T; Department of Medical Oncology, Fukuchiyama City Hospital, Kyoto, Japan., Nishioka N; Department of Pulmonary Medicine, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan., Iwasaku M; Department of Pulmonary Medicine, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan., Tokuda S; Department of Pulmonary Medicine, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan., Takayama K; Department of Pulmonary Medicine, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan.

المصدر: The oncologist [Oncologist] 2024 May 03; Vol. 29 (5), pp. e681-e689.

نوع المنشور: Journal Article; Multicenter Study; Observational Study; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Oxford University Press Country of Publication: England NLM ID: 9607837 Publication Model: Print Cited Medium: Internet ISSN: 1549-490X (Electronic) Linking ISSN: 10837159 NLM ISO Abbreviation: Oncologist Subsets: MEDLINE

مواضيع طبية MeSH: Ramucirumab* , Carcinoma, Non-Small-Cell Lung*/drug therapy , Carcinoma, Non-Small-Cell Lung*/pathology , Docetaxel*/administration & dosage , Docetaxel*/therapeutic use , Lung Neoplasms*/drug therapy , Lung Neoplasms*/pathology , Lung Neoplasms*/mortality , Antibodies, Monoclonal, Humanized*/therapeutic use , Antibodies, Monoclonal, Humanized*/administration & dosage , Antineoplastic Combined Chemotherapy Protocols*/therapeutic use, Humans ; Male ; Female ; Prospective Studies ; Aged ; Middle Aged ; Aged, 80 and over ; Immunotherapy/methods ; Adult

المؤلفون: Bria E; Comprehensive Cancer Center, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Università Cattolica del Sacro Cuore, Rome, Italy., Morgillo F; Medical Oncology and Haematology, Department of Precision Medicine, University of Campania 'Luigi Vanvitelli,' Naples, Italy., Garassino MC; Department of Hematology/Oncology, The University of Chicago, Chicago, IL, USA., Ciardiello F; Medical Oncology, Department of Precision Medicine, University of Campania Luigi Vanvitelli, Naples, Italy., Ardizzoni A; Division of Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy., Stefani A; Medical Oncology, Università Cattolica del Sacro Cuore, Rome, Italy., Verderame F; Medical Oncology Unit, Ospedale Cervello Villa Sofia, Palermo, Italy., Morabito A; Thoracic Medical Oncology, National Tumor Institute 'Fondazione G Pascale,' IRCCS, Naples, Italy., Chella A; Pneumology Unit, Azienda Ospedaliero Universitaria Pisana, Pisa, Italy., Tonini G; Department of Oncology, Campus Bio-Medico University, Rome, Italy., Gilli M; Unit of Pulmonary Oncology, University of Campania 'L. Vanvitelli,' Monaldi Hospital, Naples, Italy., Del Signore E; Division of Thoracic Oncology, European Institute of Oncology, IRCCS, Milan, Italy., Berardi R; Department of Medical Oncology, Università Politecnica delle Marche, Ancona, Italy., Mencoboni M; Oncology Unit, Villa Scassi Hospital, ASL3-Genovese, Genoa, Italy., Bearz A; Department of Medical Oncology, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, Aviano, Italy., Delmonte A; IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) 'Dino Amadori,' Meldola, Italy., Migliorino MR; Pulmonary Oncology Unit, Azienda Ospedaliera San Camillo Forlanini Hospital, Rome, Italy., Gridelli C; Division of Medical Oncology, A.O.S.G. Moscati, Avellino, Italy., Pazzola A; Medical Oncology Unit, University Hospital (AOU) of Sassari, Sassari, Italy., Iero M; Medical Dep-Oncology, Roche S.p.A., Monza, Italy., De Marinis F; Thoracic Oncology Division, European Institute of Oncology (IEO), IRCCS, Milan, Italy.

المصدر: The oncologist [Oncologist] 2024 May 03; Vol. 29 (5), pp. e690-e698.

نوع المنشور: Journal Article; Clinical Trial, Phase III; Multicenter Study; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Oxford University Press Country of Publication: England NLM ID: 9607837 Publication Model: Print Cited Medium: Internet ISSN: 1549-490X (Electronic) Linking ISSN: 10837159 NLM ISO Abbreviation: Oncologist Subsets: MEDLINE

مواضيع طبية MeSH: Carboplatin*/administration & dosage , Carboplatin*/therapeutic use , Etoposide*/administration & dosage , Etoposide*/therapeutic use , Small Cell Lung Carcinoma*/drug therapy , Small Cell Lung Carcinoma*/pathology , Lung Neoplasms*/drug therapy , Lung Neoplasms*/pathology , Lung Neoplasms*/mortality , Antineoplastic Combined Chemotherapy Protocols*/therapeutic use , Antineoplastic Combined Chemotherapy Protocols*/adverse effects , Antibodies, Monoclonal, Humanized*/therapeutic use , Antibodies, Monoclonal, Humanized*/administration & dosage , Antibodies, Monoclonal, Humanized*/adverse effects, Humans ; Male ; Female ; Middle Aged ; Aged ; Adult ; Aged, 80 and over

المؤلفون: Pu X; Department of Medical Oncology, Lung Cancer and Gastrointestinal Unit, Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China., Xiao Z; Department of Oncology, The First People's Hospital of Changde City, Changde, China., Li J; Department of Thoracic Medical Oncology, Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China., Wu Z; Department of Oncology, The First People's Hospital of Changde City, Changde, China., Ma Z; Department of Thoracic Oncology Surgery, The First People's Hospital of Chenzhou City, Chenzhou, China., Weng J; Department of Oncology, Yueyang Central Hospital, Yueyang, China., Xiao M; Department of Oncology, Hunan Province Directly Affiliated Traditional Chinese Medicine Hospital, Zhuzhou, China., Chen Y; Department of Hematology and Oncology, The Second Affiliated Hospital of University of South China, Hengyang, China., Cao Y; Department of Hematology and Oncology, The First Hospital of Changsha, Changsha, China., Cao P; Department of Oncology, The Third Xiangya Hospital of Central South University, Changsha, China., Wang Q; Department of Thoracic Medical Oncology, Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China., Xu Y; Department of Thoracic Medical Oncology, Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China., Li K; Department of Thoracic Medical Oncology, Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China., Chen B; Department of Thoracic Medical Oncology, Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China., Xu F; Department of Thoracic Medical Oncology, Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China., Liu L; Department of Thoracic Medical Oncology, Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China., Kong Y; Department of Thoracic Medical Oncology, Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China., Zhang H; Department of Oncology, The Central Hospital of Shaoyang, Shaoyang, China., Duan H; Department of Oncology, People's Hospital of Hunan Province, Changsha, China., Wu L; Department of Thoracic Medical Oncology, Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China. Electronic address: wulin-calf@vip.163.com.

المصدر: Lung cancer (Amsterdam, Netherlands) [Lung Cancer] 2024 May; Vol. 191, pp. 107538. Date of Electronic Publication: 2024 Mar 18.

نوع المنشور: Journal Article; Clinical Trial, Phase II; Randomized Controlled Trial; Multicenter Study; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Elsevier Scientific Publishers Country of Publication: Ireland NLM ID: 8800805 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1872-8332 (Electronic) Linking ISSN: 01695002 NLM ISO Abbreviation: Lung Cancer Subsets: MEDLINE

مواضيع طبية MeSH: Carcinoma, Non-Small-Cell Lung*/drug therapy , Carcinoma, Non-Small-Cell Lung*/mortality , Carcinoma, Non-Small-Cell Lung*/pathology , Docetaxel*/administration & dosage , Docetaxel*/therapeutic use , Lung Neoplasms*/drug therapy , Lung Neoplasms*/mortality , Lung Neoplasms*/pathology , Indoles*/administration & dosage , Indoles*/therapeutic use , Antineoplastic Combined Chemotherapy Protocols*/therapeutic use , Antineoplastic Combined Chemotherapy Protocols*/adverse effects , Quinolines*/administration & dosage , Quinolines*/therapeutic use , Quinolines*/adverse effects, Humans ; Male ; Female ; Middle Aged ; Aged ; Adult ; Neoplasm Staging ; Treatment Outcome ; Aged, 80 and over

المؤلفون: Kaneko A; Department of Pulmonology, Yokohama City University Graduate School of Medicine, Yokohama, Japan., Kobayashi N; Department of Pulmonology, Yokohama City University Graduate School of Medicine, Yokohama, Japan., Miura K; Department of Respiratory Medicine, Yokohama Sakae Kyosai Hospital, Yokohama, Japan., Matsumoto H; Department of Pulmonology, Yokohama City University Graduate School of Medicine, Yokohama, Japan., Somekawa K; Department of Pulmonology, Yokohama City University Graduate School of Medicine, Yokohama, Japan., Hirose T; Department of Pulmonology, Yokohama City University Medical Center, Yokohama, Japan., Kajita Y; Department of Pulmonology, Yokohama City University Medical Center, Yokohama, Japan., Tanaka A; Department of Pulmonology, Yokohama City University Medical Center, Yokohama, Japan., Teranishi S; Department of Pulmonology, Yokohama City University Medical Center, Yokohama, Japan., Sairenji Y; Department of Respiratory Medicine, Yokohama Sakae Kyosai Hospital, Yokohama, Japan., Kawashima H; Department of Respiratory Medicine, Kanto Rosai Hospital, Kawasaki, Japan., Yumoto K; Department of Respiratory Medicine, Yokohama Minami Kyosai Hospital, Ykohama, Japan., Tsukahara T; Department of Respiratory Medicine, Chigasaki Municipal Hospital, Chigasaki, Japan., Fukuda N; Department of Respiratory Medicine, Fujisawa Municipal Hospital, Fujisawa, Japan., Nishihira R; Department of Respiratory Medicine, Kanto Rosai Hospital, Kawasaki, Japan., Watanabe K; Department of Pulmonology, Yokohama City University Graduate School of Medicine, Yokohama, Japan., Horita N; Department of Pulmonology, Yokohama City University Graduate School of Medicine, Yokohama, Japan., Hara Y; Department of Pulmonology, Yokohama City University Graduate School of Medicine, Yokohama, Japan., Kudo M; Department of Pulmonology, Yokohama City University Medical Center, Yokohama, Japan., Miyazawa N; Department of Respiratory Medicine, Yokohama Nanbu Hospital, Yokohama, Japan., Kaneko T; Department of Pulmonology, Yokohama City University Graduate School of Medicine, Yokohama, Japan.

المصدر: Thoracic cancer [Thorac Cancer] 2024 May; Vol. 15 (15), pp. 1208-1217. Date of Electronic Publication: 2024 Apr 11.

نوع المنشور: Journal Article; Multicenter Study

بيانات الدورية: Publisher: Wiley Publishing Asia Pty Ltd Country of Publication: Singapore NLM ID: 101531441 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1759-7714 (Electronic) Linking ISSN: 17597706 NLM ISO Abbreviation: Thorac Cancer Subsets: MEDLINE

مواضيع طبية MeSH: Carcinoma, Non-Small-Cell Lung*/drug therapy , Carcinoma, Non-Small-Cell Lung*/pathology , Lung Neoplasms*/drug therapy , Lung Neoplasms*/pathology , Antibodies, Monoclonal, Humanized*/therapeutic use , Antibodies, Monoclonal, Humanized*/administration & dosage , Ipilimumab*/therapeutic use , Ipilimumab*/administration & dosage , Antineoplastic Combined Chemotherapy Protocols*/therapeutic use , Nivolumab*/therapeutic use , Nivolumab*/administration & dosage, Humans ; Female ; Male ; Retrospective Studies ; Middle Aged ; Aged ; Adult ; Aged, 80 and over